DelveInsight's "Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Cytokine Release Syndrome market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Cytokine Release Syndrome market shares of the individual therapies, a detailed current Cytokine Release Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients who are treated with immunotherapy and may or may not accompany Cytokine Release Syndrome.
- The total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM was 3,371 in 2020. Among the European 5 countries, Germany had the highest population of Cytokine Release Syndrome with 199 cases, followed by France and the United Kingdom with 175 and 161 cases respectively. On the other hand, Spain had the lowest population of 90 cases in 2020.
- The total number of Hematologic malignancies [includes ALL, B-Cell NHL (DLBCL, FL, PMBCL, etc.) & Multiple Myeloma] patients receiving CART-therapies in the 7MM were 4,389 in 2020.
Cytokine Release Syndrome Market Growth
The Cytokine Release Syndrome market analysis section of the report helps to understand the current and forecasted Cytokine Release Syndrome market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Cytokine Release Syndrome market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cytokine Release Syndrome Therapeutics Market
The rising usage of CAR-T cell therapies has prompting pharmaceutical companies to develop new therapies to prevent and treat Cytokine Release Syndrome in order to provide safe treatment options. As per DelveInsight, the Cytokine Release Syndrome market size is expected to increase during the forecast period owing to the launch of emerging therapies. The rise in the incidence of Cytokine Release Syndrome stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across the globe have shifted their focus toward the treatment of Cytokine Release Syndrome. The increase in the incidence will potentiate the Cytokine Release Syndrome treatment market.
Cytokine Release Syndrome Companies
- Incyte Corporation
- Jazz Pharmaceuticals
- Sobi
And many others.
Cytokine Release Syndrome Therapies covered in the report include:
- Itacitinib
- Defibrotide
- Anakinra
And many more.
Cytokine Release Syndrome Epidemiology
Cytokine Release Syndrome Epidemiology Segmentation
- Total Number of B-cell NHL Patients receiving CAR T-Cell Therapies
- Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies
- Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies
- Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies
- Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade
The Cytokine Release Syndrome epidemiology section covers insights about historical and current Cytokine Release Syndrome patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Cytokine Release Syndrome Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Cytokine Release Syndrome Market Growth